Cargando…
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145905/ https://www.ncbi.nlm.nih.gov/pubmed/37111346 http://dx.doi.org/10.3390/ph16040590 |